Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: Capt who wrote (108313)	2/13/2004 1:08:55 PM
From: Findit	Read Replies (1) \| Respond to of 208838

CRDM volume still good, but mm's are moving it up/down/up/down etc between 1.20 and 1.24 now. Hopefully they will let it go. This one has provided many HF's in the past. This does have the advantage for those that end up being stuckholders in that long term this company looks real good. MHO. Jim

To: Capt who wrote (108313)	2/16/2004 12:03:11 PM
From: Findit	Read Replies (3) \| Respond to of 208838

This TRIB news is a little old, but here is it anyway. NEW YORK, February 5 (New Ratings) — Analyst Stephen L Handley of JM Dutton & Associates upgrades Trinity Biotech plc (Dublin: TRIB.I - news) (TRIB) to "speculative buy." The target price is set to $5.25. In a research note published this morning, the analyst mentions that Trinity Biotech has received the FDA approval for marketing and labeling its new HIV test. JM Dutton & Associates expects the company's proposed direct sales-force expansion in the US to further boost its sales growth and gross margins expansion in the forthcoming years. The current valuation of Trinity Biotech's stock is attractive, following the recent share price weakness, the analyst believes. © 2004 New Ratings